Skip to content
medxy logo Medxy AI
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • facebook.com
  • twitter.com
  • t.me
  • instagram.com
  • youtube.com
Subscribe
  • Home
  • economics
HNC-8D: A Head and Neck Cancer–Specific Utility Measure That Improves Discrimination of Post‑treatment Health States
Posted innews Oncology Otorhinolaryngology

HNC-8D: A Head and Neck Cancer–Specific Utility Measure That Improves Discrimination of Post‑treatment Health States

Posted by MedXY By MedXY 11/21/2025
A multinational team developed and valued the HNC-8D, an 8-dimension, head and neck cancer–specific health utility instrument derived from EORTC QLQ-C30/H&N43. Valuation in 250 participants yielded mean absolute prediction errors of 0.041 (discovery) and 0.082 (validation).
Read More
  • Biventricular Pacing Outperforms Conduction System Pacing in Heart Failure: Key Insights from PhysioSync-HF Trial
  • Inflammatory and Cardiac Biomarkers Predict VTE and Bleeding Risks in Cancer Patients
  • Focal vs. Diffuse Coronary Artery Disease: How Disease Pattern Influences PCI’s Placebo-Controlled Symptom Relief in ORBITA-2
  • Unraveling the Gut-Heart Connection: How Leaky Gut Fuels Atrial Fibrillation in Aging
  • Survival of Patients Diagnosed With Cancer During the COVID-19 Pandemic
  • About us
  • Contact us
  • MedXY story
  • Privacy Policy
  • Subscribe Now!
  • 账号

  • English
  • 日本語
  • Tiếng Việt
  • 中文

Alzheimer's disease artificial intelligence atrial fibrillation biomarkers breast cancer Cardiology cardiovascular disease cardiovascular risk chronic kidney disease clinical trial clinical trials critical care depression diabetes epidemiology health heart failure Hypertension immunotherapy inflammation MASLD mental health metformin Mortality multiple myeloma myocardial infarction nutrition obesity older adults oncology Pediatrics precision medicine Pregnancy prevention prostate cancer public health randomized clinical trial randomized trial SGLT2 inhibitors stroke targeted therapy type 1 diabetes type 2 diabetes weight loss women's health

Your health, we care

Copyright 2026 — Medxy AI. All rights reserved.
Scroll to Top
Sign in